fda glp 1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Ban on Compounded GLP-1
Description
doi: 10.2337/dc20-1890 46 DonnanGAFisherMMacleodMDavisSM

Studies involving adult IIH patients treated with GLP-1 RAs and reporting relevant clinical outcomes were included

26 August 2008
Noom earns a perfect score here

Discussion Endothelial dysfunction can be considered as a valuable biomarker for predicting atherosclerosis and other cardiovascular lesions 10

von Scholten, B